Solara Active Pharma Sciences Limited — Updates, 15-05-2025: Press Release

Solara has announced a board meeting on May 15, 2025. FY25 revenues were stable at INR 1,292.1 Cr amid tough competition in Ibuprofen. Gross margin jumped to 51.5% (+1370 bps YoY) due to a stronger Regulated market mix and profitable product focus. EBITDA swung positive to INR 213.8 Cr (16.5% margin) from a loss last year, backed by cost control and margin gains. Gross debt fell to INR 776 Cr, with more reduction expected after the Rights Issue. Plans include carving out CRAMS and Polymers to unlock value, aiming for 10%-20% revenue and EBITDA growth in FY26.